Cerenome, Inc.
CNSY
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.36M
Close$
Share Statistics
| Market cap | $9.36 Million |
|---|---|
| Enterprise Value | $7.04 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -477.54% |
|---|---|
| Return on Assets | -185.94% |
| Return on Invested Capital | 366.70% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.44 |
| Enterprise Value to EBIT | 0.35 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Plus Therapeutics Inc
2,018 employees
CEO: Marc Hedrick Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...